# US 2026/0218180 A1 · Products and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218180 A1
- Document ID: US20260218180A1
- Status: Published application
- Kind: A1
- Application number: 19/142,520
- Filed: 2023-12-22
- Published: 2026-07-30
- Earliest claimed: 2022-12-22
- Assignees: Sirnaomics, Inc.
- Applicants: Sirnaomics, Inc.
- Inventors: Jack Wei; Dmitry Samarsky
- Web page: https://patentgrep.com/patent/US20260218180A1

## CPC

- A61P 3/06: Antihyperlipidemics
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4245: Oxadiazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/351: Conjugate
- C12N 2310/3513: Protein; Peptide
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to nucleic acid products that interfere with or inhibit APOC3 and AGT gene expression, together with methods for using the nucleic acids in the treatment of subjects.

## Claims

### Claim 1

A nucleic acid construct comprising or consisting of:
(a) a first nucleic acid portion that is at least partially complementary to at least a first portion of an RNA which is transcribed from an APOC3 gene;
(b) a second nucleic acid portion that is at least partially complementary to at least a second portion of an RNA which is transcribed from an AGT gene;
(c) a third nucleic acid portion that is at least partially complementary to said first nucleic acid portion of (a), so as to form a first nucleic acid duplex region therewith;
(d) a fourth nucleic acid portion that is at least partially complementary to said second nucleic acid portion of (b), so as to form a second nucleic acid duplex region therewith,
said construct is designed such that subsequent to in vivo administration said construct disassembles to yield at least first and second discrete nucleic acid targeting molecules that respectively target said RNA portions transcribed from said target genes of (a) and (b); whereby
(i) said first nucleic acid targeting molecule is capable of modulating expression of said target gene of (a), and comprises, or is derived from, at least said first nucleic acid portion of (a),
and (ii) said second nucleic acid targeting molecule is capable of modulating expression of said target gene of (b), and comprises, or is derived from, said second nucleic acid portion of (b),
said construct is designed to disassemble such that said first and second discrete nucleic acid targeting molecules are respectively processed by independent RNAi-induced silencing complexes.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The construct according to claim 1, which further comprises at least one labile functionality such that subsequent to in vivo administration said construct is cleaved so as to yield said at least first and second discrete nucleic acid targeting molecules,
said labile functionality comprises one or more unmodified nucleotides,
said one or more unmodified nucleotides of said labile functionality represent one or more cleavage positions within said construct whereby subsequent to in vivo administration said construct is cleaved at said one or more cleavage positions so as to yield said at least first and second discrete nucleic acid targeting molecules,
said cleavage positions are respectively located within the construct so that after cleavage said first discrete nucleic acid targeting molecule comprises, or is derived from, said first nucleic acid duplex region, and said second discrete nucleic acid targeting molecule comprises, or is derived from, said second nucleic acid duplex region,
said first discrete nucleic acid targeting molecule comprises or consists of said first nucleic acid portion of (a) and said third nucleic acid portion of (c), and/or said second discrete nucleic acid targeting molecule comprises or consists of said second nucleic acid portion of (b) and said fourth nucleic acid portion of (d).

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The construct according to claim 1, wherein
(a) said first nucleic acid portion has a nucleobase sequence selected from SEQ ID NOs: 1 to 30;
(b) said second nucleic acid portion has a nucleobase sequence selected from SEQ ID NOs: 61 to
(c) said third nucleic acid portion has a nucleobase sequence selected from SEQ ID NOs: 31 to 60; and/or
(d) said fourth nucleic acid portion has a nucleobase sequence selected from SEQ ID NOs: 91 to 120.

### Claim 10 (depends on 1)

The construct according to claim 1, wherein said first nucleic acid portion of (a) is directly or indirectly linked to said fourth nucleic acid portion of (d) as a primary structure,
said second nucleic acid portion of (b) is directly or indirectly linked to said third nucleic acid portion of (c) as a primary structure,
said first nucleic acid portion has the nucleobase sequence of SEQ ID NO: 3, and/or said second nucleic acid portion has a nucleobase sequence selected from SEQ ID NOs: 61, 66, 67, 73, 68 and 76, and/or said third nucleic acid portion has the nucleobase sequence of SEQ ID NO: 33, and/or said fourth nucleic acid portion has a nucleobase sequence selected from SEQ ID NOS: 91, 96, 97, 103, 98 and 106.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The construct according to claim 1, that further comprises_1 to 8, advantageously 2, additional nucleic acid portions that are respectively at least partially complementary to an additional 1 to 8 portions of RNA transcribed from one or more target genes, which target genes may be the same or different to each other, and/or the same or different to the target genes defined in (a) and/or (b), and wherein each of the 1 to 8 additional nucleic acid portions respectively form additional duplex regions with respective passenger nucleic acid portions that are respectively at least partially complementary therewith, said second nucleic acid portion of (b), and said 1 to 8 additional nucleic acid portions, are directly or indirectly linked to selected passenger nucleic acid portions as respective primary structures.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The construct according to claim 14, wherein said direct or indirect linking represents either (i) an internucleotide bond, said linking is direct, thereby giving rise to (a) contiguous strand(s), there exists some complementarity between the first nucleic acid portion of (a) and the second nucleic acid portion of (b), or the third nucleic acid portion of (c) and the fourth nucleic acid portion of (d), said complementarity
(i) is/are 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, advantageously 2, 3, 4 or 5 base pairs; and/or
(ii) is between the first nucleic acid portion of (a) and the second nucleic acid portion of (b), said internucleotide bond involves at least one of said one or more unmodified nucleotides, wherein advantageously cleavage occurs at the 3′ position of (at least one of) said unmodified nucleotide(s),
or (ii) a nucleic acid linker portion of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides, said nucleic acid linker advantageously being single stranded.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The construct according to claim 1, wherein said first nucleic acid portion of (a), and/or said second nucleic acid portion of (b), and/or said third nucleic acid portion of (c), and/or said fourth nucleic acid portion of (d), are respectively 7 to 25 nucleotides in length,
first nucleic acid portion of (a) and/or said second nucleic acid portion of (b) have a length of 18 to 21, more advantageously 18 to 20, and yet more advantageously 19 nucleotides,
and/or wherein said third nucleic acid portion of (c), and/or said fourth nucleic acid portion of (d) have a length of 11 to 20, more advantageously 13 to 16, and yet more advantageously 14 or 15, most advantageously 15 nucleotides,
said unmodified nucleotide(s) is/are at any of position 18 to 25, more advantageously at any of positions 18 to 21 and/or the 3′ terminal position of said first nucleic acid portion of (a) and/or of said third nucleic acid portion of (c), advantageously unmodified nucleotide is at position 19.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 16)

The construct according to claim 16, wherein said nucleic acid linker portion is 1 to 8 nucleotides in length, advantageously 2 to 7 or 3 to 6 nucleotides in length, more advantageously about 4 or 5 and most advantageously 4 nucleotides in length,
one, more of all of the duplex regions independently have a length of 10 to 19, more advantageously 13 to 19, and yet more advantageously 13, 14 or 15 base pairs, most advantageously 15 base pairs, wherein optionally there is one mismatch within said duplex region,
further comprises one or more ligands, one or more ligands are any cell directing moiety, such as lipids, carbohydrates, aptamers, vitamins and/or peptides that bind cellular membrane or a specific target on cellular surface, one or more ligands are conjugated at the 3′ region,
advantageously the 3′ end, of any of (i) said third nucleic acid portion of (c), and/or (ii) said fourth nucleic acid portion of (d), and/or, to the extent present, said (iii) passenger nucleic acid portions,
said first nucleic acid portion of (a), and/or said second nucleic acid portion of (b), and/or said third nucleic acid portion of (c), and/or said fourth nucleic acid portion of (d), and/or, to the extent present, said 1 to 8 additional nucleic acid portions, and/or said passenger nucleic acid portions, respectively have a 51 to 31 directionality thereby defining 51 and 31 regions thereof.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 26)

The construct according to claim 26, wherein said one or more carbohydrates can be a monosaccharide, disaccharide, tri saccharide, tetrasaccharide, oligosaccharide or polysaccharide,
said one or more carbohydrates comprise one or more hexose moieties,
said one or more hexose moieties are one or more galactose moieties, one or more lactose moieties, one or more N-Acetyl-Galactosamine moieties, and/or one or more mannose moieties, advantageously comprises two or three N-Acetyl-Galactosamine moieties,
and/or one or more ligands are attached in a linear configuration, or in a branched configuration, one or more ligands are attached as a biantennary or triantennary configuration, or as a configuration based on single ligands at different positions, advantageously said ligand has the following structure:

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 34)

The construct according to claim 34, which comprises one or more phosphorothioate or phosphorodithioate internucleotide linkages at one or more of the 51 and/or 31 regions of said first nucleic acid portion of (a), and/or said second nucleic acid portion of (b), and/or said third nucleic acid portion of (c), and/or said fourth nucleic acid portion of (d), and/or said 1 to 8 additional nucleic acid portions, and/or said passenger nucleic acid portions, and/or comprises phosphorothioate or phosphorodithioate internucleotide linkages between at least two adjacent nucleotides of the nucleic acid linker portion.

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 16)

The construct according to claim 16, wherein at least one nucleotide of at least one of the following is modified: the first nucleic acid portion of (a); and/or the second nucleic acid portion of (b); and/or the third nucleic acid portion of (c); and/or the fourth nucleic acid portion of (d); and/or to the extent present, the 1 to 8 additional nucleic acid portions; and/or to the extent present, the passenger nucleic acid portions; and/or to the extent present, the nucleic acid linker portion.

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60 (depends on 47)

The construct according to claim 47, wherein the modification and/or modifications are each and individually sugar, phosphate, or base modifications, advantageously the modification is selected from nucleotides with 2′ modified sugars; conformationally restricted nucleotides (CRN) sugar such as locked nucleic acid (LNA), (S)-constrained ethyl bicyclic nucleic acid, and constrained ethyl (cEt), tricyclo-DNA;
morpholino, unlocked nucleic acid (UNA), glycol nucleic acid (GNA), D-hexitol nucleic acid (HNA), and cyclohexene nucleic acid (CeNA),
said 2′ modified sugar is selected from 2′-O-alkyl modified sugar, 2′-O-methyl modified sugar, 2′-O-methoxy ethyl modified sugar, 2′-O-allyl modified sugar, 2′-C-allyl modified sugar, 2′-deoxy modified sugar such as 2′-deoxy ribose, 2′-F modified sugar, 2′-arabino-fluoro modified sugar, 2′-O-benzyl modified sugar, 2′-amino modified sugar, and 2′-O-methyl-4-pyridine modified sugar,
at least one modification is a 2′-O-methyl modification in a ribose moiety,
at least one modification is a 2′-F modification in a ribose moiety.

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73 (depends on 1)

The construct according to claim 1, wherein said construct comprises a first strand, and a second strand, wherein the nucleobase sequences of said first and said second strands are SEQ ID NO: 130 and 131, SEQ ID NO: 132 and 133, SEQ ID NO: 134 and 135, SEQ ID NO: 136 and 137, SEQ ID NO: 138 and 139, SEQ ID NO: 140 and 141, SEQ ID NO: 142 and 143, SEQ ID NO: 144 and 145, or SEQ ID NO: 146 and 147, respectively.

### Claim 74 (depends on 73)

The construct according to claim 73, wherein the construct is selected from the group consisting of SEQ ID Nos. 148-165.

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78

(canceled)

### Claim 79 (depends on 1)

The construct according to claim 1, which is blunt ended, the target RNA is an mRNA or another RNA molecule.

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84 (depends on 1)

A pharmaceutical composition comprising a nucleic acid construct according to claim 1.

### Claim 85 (depends on 84)

The pharmaceutical composition of claim 84, further comprising a pharmaceutically acceptable excipient, diluent, antioxidant, and/or preservative, and/or said pharmaceutical composition furthermore comprises one or more further pharmaceutically active agents,
said further pharmaceutically active agents are selected from Vascepa; Vupanorsen; statins such as Rosuvastatin and Simvastatin; fibrates such fenofibrate; LDL-cholesterol lowering compounds such as statins and ezetimib, and/or
agents which decrease hypertension, wherein said further pharmaceutically active agent(s) is/are optionally selected from the group consisting of a diuretic, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, a beta-blocker, a vasodilator, a calcium channel blocker, an aldosterone antagonist, an alpha2-agonist, a renin inhibitor, an alpha-blocker, a peripheral acting adrenergic agent, a selective DI receptor partial agonist, a nonselective alpha-adrenergic antagonist, a synthetic, a steroidal antimineralocorticoid agent; a combination of any of the foregoing; and a hypertension therapeutic agent formulated as a combination of agents, more optionally an angiotensin II receptor antagonist selected from the group consisting of losartan, valsartan, olmesartan, eprosartan, and azilsartan.

### Claim 86

(canceled)

### Claim 87

(canceled)

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90

(canceled)

### Claim 91

(canceled)

### Claim 92

(canceled)

### Claim 93

(canceled)

### Claim 94 (depends on 1)

A method of treating a disease or disorder comprising administration of a nucleic acid construct according to claim 1, to an individual in need of treatment.

### Claim 95 (depends on 94)

The method according to claim 94, wherein the nucleic acid construct is administered subcutaneously or intravenously to the individual,
said disease or disorder is a disease or disorder associated with APOC3 and/or AGT or a disease or disorder requiring reduction of APOC3 and/or AGT expression,
said disease or disorder is selected from the group consisting of an APOC3-associated disease or disorder, or a disease or disorder requiring reduction of APOC3 expression levels, said disease or disorder advantageously being selected from dyslipidemia including mixed dyslipidemia;
hyperchylomicronemia including familial hyperchylomicronemia; hypertriglyceridemia, advantageously severe hypertriglyceridemia and/or hypertriglyceridemia with blood triglyceride levels above 500 mg/dl; inflammation including low-grade inflammation; atherosclerosis;
atherosclerotic cardiovascular diseases (ASCVD) including major adverse cardiovascular events (MACE) such as myocardial infarction, stroke and peripheral arterial disease; pancreatitis including acute pancreatitis; and/or
high blood pressure, hypertension, borderline hypertension, primary hypertension, secondary hypertension isolated systolic or diastolic hypertension, pregnancy-associated hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, labile hypertension; hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiac myopathy, nocturnal hypotension, glomerulosclerosis, coarctation of the aorta, aortic aneurism, ventricular fibrosis, heart failure, myocardial infarction, angina, stroke, renal disease, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, liver steatosis/fatty liver, non-alcoholic Steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes, and metabolic syndrome.

### Claim 96 (depends on 1)

Use of a nucleic acid construct according to claim 1, for use in research as a gene function analysis tool, or for use in the manufacture of a medicament for a treatment of a disease or disorder.

### Claim 97

(canceled)
